Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans

Allabi, AC; Gala, JL; Horsmans, Y; Babaoglu, MO; Bozkurt, ATİLLA; Heusterspreute, M; Yasar, ÜMİT

doi:10.1016/j.clpt.2004.04.001

Functional impact of CYP2C5, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans

Allabi A., Gala J., Horsmans Y., Babaoglu M., Bozkurt A., Heusterspreute M., ...Daha Fazla

CLINICAL PHARMACOLOGY & THERAPEUTICS, cilt.76, sa.2, ss.113-118, 2004 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 76 Sayı: 2
Basım Tarihi: 2004
Doi Numarası: 10.1016/j.clpt.2004.04.001
Dergi Adı: CLINICAL PHARMACOLOGY & THERAPEUTICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.113-118
Hacettepe Üniversitesi Adresli: Evet

Özet

Background and Aim: Previous data indicate that the urinary losartan/E-3174 ratio is a marker for cytochrome P450 (CYP) 2C9 activity in vivo. The functional impact of CYP2C9(star)5, (star)6, (star)8, and (star)11 polymorphisms in vivo has not been investigated previously in humans.